Sativex approved in Sweden

Published: 22-Dec-2011
Regulatory

For the treatment of spasticity due to multiple sclerosis


The Medical Products Agency in Sweden has granted regulatory approval to GW Pharmaceuticals’ cannabis-based medicine Sativex as a treatment for moderate to severe spasticity due to multiple sclerosis.

Sativex (Delta-9-Tetrahydro-cannabinol (THC) and Cannabidiol (CBD)) oromucosal spray is currently available in the UK, Germany, Spain and Denmark.

Clinical trials have shown that the drug has a positive impact on spasticity in MS, while alleviating associated symptoms including pain, bladder or sleep disturbance.

Sativex is also in phase III clinical development for the treatment of cancer pain.

GW’s marketing partner Almirall will start marketing the drug in Sweden during the first half of 2012 following completion of the national pricing and reimbursement process.

Almirall holds the marketing rights to this medicine in Europe (except the UK).

  • Companies:
  • GW Pharmaceuticals
See more

You may also like

Regulatory

GW Pharmaceuticals gains product recognition by NHS England

Read more
Epidyolex (cannabidiol) oral solution and Sativex (nabiximols) have been recommended for use by the UK’s National Institute for Health and Care Excellence

Trending Articles

  1. Accelerating and enhancing toxicology assessments Infographic guides users through ToxHQ’s speedy assessment features
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  3. Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Why quality control should be intimately combined with sterile product development, manufacturing and the overall product supply chain With sponsor companies increasingly needing to create and launch differentiated, stable, usable and safe injectable treatments for patients, experts at ten23 health are keen to promote the importance of integrating development and/or manufacturing with quality control services
  5. The right validation model: practical considerations and applications It is widely accepted that validation in the life sciences industry follows a lifecycle model (1,2). What is not always clear is the specific model — or models — to follow and how to navigate through them in the real world. Hurdles to overcome include the specific deliverables that make up that model and how they change during the various interactions along the validation journey

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Regulatory

GW Pharmaceuticals gains product recognition by NHS England

Epidyolex (cannabidiol) oral solution and Sativex (nabiximols) have been recommended for use by the UK’s National Institute for Health and Care Excellence
Manufacturing

Momentum in the US cannabidiol market gains retailers' attention

Walmart and other big-name stores in talks with food and drinks makers in preparation for the day CBD-enriched products are allowed on the shelves
Regulatory

First prescription CBD from GW Pharma has restriction lowered

The US Drug Enforcement Administration’s decision to move Epidiolex to Schedule V was based on non-clinical and clinical data that evaluated the medicine’s potential for abuse
Regulatory

First plant-derived cannabinoid prescription gains FDA approval

GW Pharmaceuticals has announced FDA approval of EPIDIOLEX (cannabidiol) oral solution, a medication prescribed for seizures associated with Lennox-Gastaut Syndrome or Dravet Syndrome
Regulatory

GW receives FDA fast track and EMA orphan designations for intravenous cannabidiol

FDA orphan designation previously granted for the neonatal hypoxic-ischaemic encephalopathy (NHIE) treatment
Regulatory

Sativex moved to Schedule 4 of UK Drugs Act

Recognises low potential for abuse and low risk of diversion
Regulatory

Sativex approved in Denmark

For the treatment of spasticity due to Multiple Sclerosis (MS)
Subscribe now